论文部分内容阅读
目的观察东菱克栓酶治疗不同亚型急性脑梗死的临床疗效。方法对拟应用东菱克栓酶治疗的急性脑梗死患者进行OCSP分型;在治疗前、用药后1d、3d、5d检测纤维蛋白原;对患者治疗前后进行中国卒中量表评分。结果OCSP各亚型急性脑梗死血浆纤维蛋白原含量在用药前无显著性差异(P>0.05),用药后1d、3d、5d血Fg较用药前降低(P<0.01),用药后1d降低更甚(P<0.01),腔隙性脑梗塞血较其他亚型下降更明显(P<0.01),各亚型治疗前后神经功能缺损程度均有显著下降(P<0.05)。结论东菱克栓酶治疗不同亚型急性脑梗死安全有效,对腔隙性脑梗塞的疗效明显高于其他亚型。
Objective To observe the curative effect of Batroxobin on different subtypes of acute cerebral infarction. Methods OCSP was performed on patients with acute cerebral infarction who were treated with tachykinase. Before treatment, fibrinogen was detected on the 1st, 3rd and 5th day after treatment. The Chinese stroke scale was scored before and after treatment. Results There was no significant difference in plasma fibrinogen levels between before and after treatment in OCSP subtypes of acute cerebral infarction patients (P> 0.05). The Fg of 1, 3 and 5 d after administration decreased significantly (P <0.01) (P <0.01), lacunar infarction blood more significantly decreased than other subtypes (P <0.01), before and after treatment of various subtypes of neurological deficit were significantly decreased (P <0.05). Conclusion Batroxobin treatment of different subtypes of acute cerebral infarction safe and effective, lacunar infarction efficacy was significantly higher than other subtypes.